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Abstract 
Review on PAWR, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Keywords 
PAWR; apoptosis; NF-kB pathway; cancer; ER-
Golgi network 
Identity 
Other names: Par-4 , PAR4 
HGNC (Hugo): PAWR 
Location: 12q21.2 
Local order 
Synaptotagmin I 12q21.2 on plus strand protein 
phosphatase 1, regulatory (inhibitor) subunit 12A 
12q21.2 on minus strand PAWR 12q21.2 on minus 
strand protein tyrosine phosphatase, receptor type, Q 
12q21.2 on plus strand. 
DNA/RNA 
Description 
Genomic regions: Par-4/PAWR gene is encoded by 
the minus strand of chromosome 12q21.2. The gene 
encompasses 99.064 kb of DNA; 7 exons and 6 
introns. ATG is located on exon 2. 
Transcription 
2.2 kb nucleotides mRNA. 1.02 kb open reading 
frame. 
Pseudogene 
Not known. 
Protein 
Description 
Human Par-4/PAWR is a about 40 kDa protein 
containing 340 amino acids. Rat Par-4 has 332 
amino acids whereas mouse Par-4 has 333 amino 
acids. Par-4/PAWR has two putative nuclear 
localization sequences in the N-terminal region and 
a leucine zipper domain and a nuclear export 
sequence in the C-terminal portion. There is a SAC 
domain (147-206 amino acids), selective for 
apoptosis induction in cancer cells. SAC domain is 
the effecter domain of Par-4/PAWR. These domains 
are 100% conserved in human, rat and mouse 
homologs. 
Expression 
Par-4/PAWR is ubiquitously expressed in normal 
mammalian tissues. However, Par-4/PAWR is 
diminished in a majority (>75% specimens) of renal 
cell carcinoma specimens.  
PAWR (PRKC apoptosis WT1 regulator protein; Prostate 
apoptosis response-4, Par-4) 
Shukla N, et al. 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(9) 474 
 
Par-4/PAWR expression is also decreased in 
endometrial tumors, lung cancer, neuroblastoma and 
in cells of patients with acute lymphatic leukemia 
and chronic lymphocytic leukemia. Par-4 is down-
regulated in breast cancer, nasopharyngeal tumors 
and glioblastoma, and this is associated with therapy 
resistance and reduced patient survival. 
Localisation 
Immonocytochemical analysis indicates that Par-
4/PAWR is predominantly localized in cytoplasm in 
normal cells and is strongly localized in cytoplasm 
and nucleus in most cancer cell lines. However, 
Western blot analysis indicates that Par-4/PAWR is 
also in the nuclear fraction of normal cells implying 
it is masked in the nucleus. Par-4 is spontaneously 
secreted by normal and cancer cells, and secreted 
Par-4 induces cancer-cell specific apoptosis through 
cell surface receptor GRP78, expressed at the surface 
of only cancer cells, not normal cells. 
Function 
Par-4/PAWR, a pro-apoptotic protein, was first 
identified in prostate cancer cells that were induced 
to undergo apoptosis. Par-4 knockout mice 
spontaneously develop tumors of the liver, lung, and 
endometrium; prostatic intraepithelial neoplasia, and 
an increased frequency of estrogen-inducible tumors 
in the endometrium and BBN-inducible tumors in 
the bladder. Endogenous Par-4/PAWR expressed in 
normal and cancer cells does not, by itself, causes 
apoptosis, yet is essential for apoptosis via diverse 
cell death pathways. Par-4/PAWR sensitizes cells to 
apoptosis by wide variety of pro-apoptotic stimuli, 
such as growth factor withdrawal, agents that elevate 
intracellular Ca2+, TNF, TRAIL, UV, X-ray and 
gamma irradiation, or IFN-gamma. Ectopic Par-
4/PAWR over-expression is by itself sufficient to 
induce apoptosis in most cancer cells, but not in 
normal or immortalized cells. The cancer selective 
pro-apoptotic function of Par-4/PAWR is localized 
in its central core SAC (Selective for Apoptosis-
induction in Cancer cells) domain (amino acids 147-
206 in human Par-4/PAWR; or 137-195 in rat Par-4) 
which is 100% conserved in human, mouse and rat. 
Apoptosis by ectopic Par-4/PAWR requires Par-
4/PAWR nuclear translocation and involves both 
activation of the Fas death receptor signaling 
pathway and NF-kappaB inhibition. Par-4/PAWR 
also inhibits the prosurvival protein Bcl-2 and down 
regulates ERK-2 expression. Neither p53 nor PTEN 
are directly required for apoptosis by Par-4/PAWR 
or the SAC domain. Par-4/PAWR has been shown to 
be i nvolved in suppression of transformation by 
down-regulation of Ras. Overexpression of Par-
4/PAWR results in apoptosis of cells expressing 
oncogenic Ras. 
Several partner proteins of Par-4/PAWR have been 
identified and partner interaction requires an intact 
Par-4/PAWR leucine zipper domain. Par-4/PAWR 
associates with aPKC resulting in inhibition of NF-
kappaB activity, interaction with WT1 results in 
transcriptional repression of Bcl-2, whereas binding 
to and phosphorylation by Akt1 results in Par-
4/PAWR cytoplasm retention by 14-3-3, thus 
isolating Par-4/PAWR from its nuclear targets.  
Par-4/PAWR also binds to DLK/ZIP kinase (ZIPK) 
and induces DAAX/ZIPK-mediated apoptosis. In 
addition, THAP1 (a novel nuclear pro-apoptotic 
factor) interacts with Par-4/PAWR and potentiates 
both serum withdrawal and TNF-induced apoptosis 
in endothelial cells. 
Par-4/PAWR is also involved in sensitization of 
neurons to apoptosis. Endogenous Par-4/PAWR is 
reported to be up-regulated in different 
neurodegenerative diseases including Alzheimer's, 
Huntington's and Parkinson's diseases and 
amyotrophic lateral sclerosis. 
Post-translational modifications: The apoptosis of 
Par-4/PAWR requires phosphorylation of the 
threonine residue (T155 in rat Par-4/PAWR) in the 
SAC domain by PKA, which is elevated in cancer 
cells. Amino acid S249 in rat Par-4/PAWR is 
phosphorylated by AKT for Par-4/PAWR cytoplasm 
retention and inactivation.  
 Par-4 is secreted via classical pathway and is 
associated with ER-stress  
Most of the studies until now have been focused on 
the intracellular role of Par-4 but Burikhanov et al. 
(2009) provided a new direction to the field with 
their discovery that Par-4 is secreted by normal or 
immortalized cells, as well as cancer cells and that 
secreted Par-4 shows cancer cell-specific apoptosis 
through cell surface HSPA5 (GRP78), which is an 
endoplasmic reticulum (ER)-resident protein 
expressed at the cell surface selectively in cancer 
cells.  
Par-4 secretion is observed in vivo and plasma or 
serum samples obtained from Par-4 transgenic mice 
contain detectable amounts of Par-4 that are 
adequate to induce apoptosis ex vivo specifically in 
cancer cells.  
Cells treated with Brefeldin A (BFA, an antiviral 
antibiotic, which blocks protein trafficking from the 
ER to cis-Golgi cisternae), decreased secretion of 
Par-4, suggesting that the secretion of Par-4 occurs 
through a BFA-sensitive classical pathway involving 
the ER-Golgi network.  
Also, Par- 4 secretion is increased upon treatment of 
cells with ER stress inducers tunicamycin (an 
inhibitor of N-linked glycosylation) and thapsigargin 
(an inhibitor of the sarcoplasmic/Endoplasmic 
Reticulum Ca+2 ATPase), which also caused 
upregulation of GRP78. 
 Par-4 is involved in the translocation of GRP78 
from ER to the cell surface  
The correlation between intracellular Par-4, GRP78 
and extracellular Par-4 in activating apoptosis has 
been further confirmed through RNAi studies. 
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Knocking down Par-4 resulted in decreased 
translocation of GRP78 to the cell surface, indicating 
that endogenous Par-4 is required for cell surface 
expression of GRP78. This finding was further 
supported by Cohen et al. who confirmed the role of 
endogenous Par-4 in binding and translocation of 
GRP78 in trophoblastic cells. For the first time, this 
study showed the presence of Par-4 in both villous 
and extra villous cytotrophoblastic cells (CTB) and 
expression of Par-4 correlated with expression of 
membrane GRP78. Also, Par-4 overexpression led to 
an increase in cell surface expression of GRP78, 
whereas reduced Par-4 expression resulted in 
reduced cell surface localization of GRP78.  The 
observations corroborate the role of Par-4 in 
translocation of GRP78 from ER to the cell surface. 
Decreased membrane GRP78 expression has been 
observed in preeclamptic (PE) cytotrophoblastic 
cells (CTB). This could be due to an altered 
expression of GRP78 transporting proteins. 
Interestingly, Par-4 protein expression was found to 
be reduced in PE CTB. This finding will help in 
better understanding of Par-4 expression, 
localization and posttranslational modifications in 
CTB to prevent PE. 
 Par-4/SAC-activity is transferable by bone 
marrow transplantation  
To analyze the functional efficacy of SAC domain, 
transgenic mice that ubiquitously express the SAC 
domain were generated. To confirm the functional 
activity of this secreted Par-4/SAC in transgenic 
mice, bone marrow of SAC-GFP-transgenic mice, 
littermate control mice or GFP-transgenic control 
mice was transferred to irradiated littermate control 
mice. Serum samples obtained from mice that 
received bone marrow cells from SAC-GFP-
transgenic mice, but not from littermate control or 
GFP-transgenic mice, induced apoptosis of 
aggressive Lewis Lung Carcinoma (LLC1) cells in 
culture. This finding implies that Par-4/SAC is 
secreted and that bone marrow transplantation is 
effective in transferring cells capable of secreting 
transgenic SAC-GFP activity into recipient mice. 
 Inhibition of lung metastasis in mice by 
recombinant Par-4/SAC  
To further confirm that Par-4/SAC activity in serum 
of transgenic mice had the potential to inhibit 
metastasis, recombinant TRX-Par-4 or TRX-SAC 
protein, which induced apoptosis of cancer cells but 
not non-transformed cells in culture, was used. TRX-
Par-4 or TRX-SAC but not TRX control protein, 
induced apoptosis in LLC1 and PC-3 cell cultures 
but not in non-transformed BPH1 cell culture. Also, 
recombinant Par-4 or SAC protein when introduced 
intravenously in immunocompetent C57BL/6 mice 
significantly inhibited lung metastasis of LLC1 cells. 
These findings confirmed that Par-4/SAC is secreted 
by normal cells and is systemically active for an 
extended period of time in suppressing tumor growth 
and metastasis in mice. A majority of the tumor 
suppressor proteins have exclusive intracellular 
mode of action, this induction of both extracellular 
and intracellular apoptotic pathways by Par-4/SAC 
is unique and can be harnessed for cancer-selective 
therapeutics. 
 Empowering Normal Cells for Paracrine 
Inhibition of Cancer  
I- P53 induces Par-4 secretion by downregulating 
UACA  
TP53 also known as the "guardian of the genome" 
acts as a tumor suppressor by intracellular activation 
of growth arrest and apoptotic cell death pathways. 
Owing to its prominent role as a tumor suppressor 
and involvement in apoptotic pathways, p53 is 
mutated in over 50% of cancers. Mutant forms of 
p53 may render cancer cells resistant to both 
chemotherapy and radiation therapy. Burikhanov et 
al. (2014) have shown that activation of p53 function 
in normal cells causes paracrine growth inhibitory 
effects in cancer cells by systemically inducing 
secretion of Par-4. Interestingly, secreted Par-4 
mediates a paracrine growth-inhibitory effect by 
inducing apoptosis of p53-deficient cancer cells. In a 
search for the direct target of p53 for inducing Par-4 
secretion, UACA, which is a binding partner of Par-
4, was identified. Previous studies have shown that 
UACA binds to Par-4 and prevents its secretion. 
UACA was lower in wild type p53 cells and mouse 
tissues relative to p53 null cells and mouse tissues, 
and UACA levels correlated inversely with the 
levels of Par-4 secreted in the CM. However, 
knocking down UACA in p53 null MEFs did not 
increase the secretion of Par-4 indicating that 
intracellular p53 function is necessary to regulate the 
secretion of Par-4.  
II- Activating p53 induces systemic expression of 
Par-4 in mice  
To investigate the role of p53 in Par-4 secretion in 
vivo, p53 wild-type mice, p53 null mice, or Par-4 
null mice were treated with Nutlin-3a, an activator of 
p53, and with PS-1145, an inhibitor of NF-kB. 
Combined treatment of Nutlin-3a and  PS-1145  
caused a 5-fold increase in serum levels of Par-4 
protein in p53 wild-type mice compared to basal 
levels in serum,  whereas it failed to elevate systemic 
levels of Par-4 in p53 null mice, suggesting that p53 
function was essential for upregulation of Par-4 
secretion. Interestingly, the serum from Nutlin-3a 
plus PS-1145-treated p53 wild-type mice, but not 
p53 null  mice or Par-4 null mice, induced ex vivo 
apoptosis of cancer cell cultures but not normal cell 
cultures. These findings suggest that p53 activation 
in normal mice induces adequate levels of systemic 
Par-4 protein that is functionally effective in 
inducing apoptosis of cancer cells. 
 Par-4 secretagogues  
As normal cells express wild type p53 function, 
recent studies have been directed toward utilizing the 
PAWR (PRKC apoptosis WT1 regulator protein; Prostate 
apoptosis response-4, Par-4) 
Shukla N, et al. 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(9) 476 
 
potential of normal immune cells or non-immune 
cells to control the growth of tumors. Studies by 
Burikhanov et al. (2014) suggest a novel cross-talk 
between p53 and Par-4 where p53 regulates the 
secretion of Par-4 via classical pathway from normal 
cells and secreted Par-4 mediates the paracrine 
apoptotic effects of p53 in a cancer-cell specific 
manner. Since the levels of Par-4 secreted by normal 
cells are not adequate to cause massive apoptosis in 
cancer cell cultures, new compounds and FDA-
approved drugs are being actively discovered as Par-
4 secretagogues. Burikhanov et al. (2014) have 
identified a novel secretagogue, Arylquin-1, a 3-
arylquinoline, which shows a dose dependent 
secretion of Par-4 from both normal fibroblasts and 
epithelial cells. This study identified VIM (vimentin) 
as a novel binding partner of Par-4 and showed that 
Arylquin-1 binds to vimentin to release vimentin-
bound Par-4 for secretion. Interestingly, Arylquin-1 
itself at low nanomolar concentrations (100-500 nM) 
did not kill normal cells and most cancer cells but it 
caused robust secretion of Par-4 from normal cells to 
induce apoptosis of cancer cells only when they were 
co-cultured. 
Homology 
The Par-4/PAWR gene has been identified in various 
organisms, including mammals (Pan Troglodytes), 
rodents (mouse, rat), chicken (Gallus gallus), 
fish(Zebrafish and Pufferfish) and tadpole. The 
nuclear localization, leucine zipper, nuclear export 
and SAC domain sequences are highly conserved. 
Mutations 
Par-4/PAWR mutations are uncommon although a 
single base mutation (Arg (CGA) 189 (TGA) Stop) 
localized in exon 3 or the SAC domain has been 
found in endometrial carcinoma. 
Implicated in 
Breast cancer 
Par-4 downregulation promotes breast cancer 
recurrence 
A recent study by Alvarez et al. (2013) has shown 
that Par-4 is a major underlying factor for breast 
cancer recurrence. Primary breast tumors consist of 
a heterogeneous population in which most cancer 
cells express Par-4 but there are some cells that show 
lower expression of Par-4. Treatment of tumors with 
chemotherapeutic agents leads to Par-4 activation 
that in turn results in multinucleation, p53 
stabilization and increased apoptosis, ultimately 
leading to tumor regression. As a result, in a 
heterogeneity population of breast tumor, cells with 
high levels of Par-4 undergo apoptosis after 
chemotherapy, whereas cells expressing low levels 
of Par-4 result in recurrence at both local and distant 
metastatic sites. 
Glioma 
Malignant gliomas are the most aggressive brain 
tumor and treating these tumors remains one of the 
greatest challenges as recurrence is very high even 
after extensive surgery or chemotherapy. 
Temozolomide (TMZ) has shown promising activity 
against gliomas but drug resistance develops in 
many cases. A novel interaction between PRNP 
(PrPc), a glycosylphosphatidylinositol-anchored 
protein and Par-4 has been shown by Zhuang et al. 
where upon TMZ treatment PrPc interacts with Par-
4 via the SAC domain and inhibits Par-4 pro-
apoptotic activity. This study shows that the 
PrPc/Par-4 complex is responsible for protecting the 
cells against apoptosis by TMZ and that disruption 
of the PrPc/Par-4 complex induces cell death. This 
study presents a novel model in which Par-4 acts as 
ligand for PrPc receptor and interaction between 
PrPc/Par-4 leads to the anti-apoptotic activity of 
glioma upon TMZ treatment. A better understanding 
of PrPc/Par-4 interaction will contribute to the 
development of strategies for treating glioma cells o 
the TMZ-based chemotherapy. 
renal cell carcinoma, and endometrial 
tumors 
Par-4/PAWR is down regulated in over 75% of clear 
cell type of renal cell carcinoma, and in endometrial 
tumors. It is mutated within its effector SAC domain 
in endometrial tumors. 
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